0000888491-23-000003.txt : 20230202 0000888491-23-000003.hdr.sgml : 20230202 20230202164215 ACCESSION NUMBER: 0000888491-23-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230202 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OMEGA HEALTHCARE INVESTORS INC CENTRAL INDEX KEY: 0000888491 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 383041398 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11316 FILM NUMBER: 23581493 BUSINESS ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 BUSINESS PHONE: 410-427-1700 MAIL ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 8-K 1 ohi-20230202x8k.htm 8-K
0000888491false00008884912023-02-022023-02-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​ ​​ ​

FORM 8-K

​ ​​ ​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2023

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in its charter)

Maryland

1-11316

38-3041398

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

303 International Circle,

Suite 200

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

(410) 427-1700

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     Written communications pursuant to Rule 425 under the Securities Act.

     Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.10 par value

OHI

New York Stock Exchange

Item 2.02     Regulation FD Disclosure

On February 2, 2023, Omega Healthcare Investors, Inc. (“Omega”) issued a press release regarding its financial results for the quarter ended December 31, 2022. Omega’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information in this Item 2.02 of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01     Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description of Exhibit

99.1Press release issued by the Company on February 2, 2023.

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OMEGA HEALTHCARE INVESTORS, INC.

Dated: February 2, 2023

By:

/s/ Gail D. Makode

Gail D. Makode

Chief Legal Officer, General Counsel

EX-99.1 2 ohi-20230202xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

303 International Circle P: 410.427.1700

Suite 200 F: 410.427.8800

Hunt Valley, MD 21030

PRESS RELEASE – FOR IMMEDIATE RELEASE

OMEGA REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS

Completed $103 Million in New Investments in Q4

Continued Operator Portfolio Restructurings

HUNT VALLEY, MARYLAND – February 2, 2023 – Omega Healthcare Investors, Inc. (NYSE: OHI) (the “Company” or “Omega”) announced today its results for the quarter and year ended December 31, 2022.  

FOURTH QUARTER 2022 AND RECENT HIGHLIGHTS

Net income for the quarter of $47 million, or $0.19 per common share, compared to $34 million, or $0.14 per common share, for the same period in 2021.
Nareit Funds From Operations (“Nareit FFO”) for the quarter was a loss of ($30) million or ($0.13) per common share, on 243 million weighted-average common shares outstanding, compared to $124 million, or $0.50 per common share, on 247 million weighted-average common shares outstanding, for the same period in 2021.
Adjusted Funds From Operations (“Adjusted FFO” or “AFFO”) for the quarter of $177 million or $0.73 per common share, compared to $190 million, or $0.77 per common share, for the same period in 2021.
Funds Available for Distribution (“FAD”) for the quarter of $171 million, compared to FAD of $179 million for the same period in 2021.
Completed $89 million in real estate acquisitions.
Funded $15 million in capital renovation and construction-in-progress projects.
Sold 33 facilities for $321 million in cash proceeds and $105 million in seller financing, generating a $180 million gain.
Declared a $0.67 per share quarterly cash dividend on common stock to be paid in February.

FULL YEAR 2022 HIGHLIGHTS

Net income for the year of $439 million, or $1.80 per common share, compared to $428 million, or $1.75 per common share, for the same period in 2021.
Nareit FFO for the year of $461 million or $1.89 per common share, on 244 million weighted-average common shares outstanding, compared to $655 million, or $2.68 per common share, on 244 million weighted-average common shares outstanding, for the same period in 2021.
AFFO for the year of $730 million or $2.99 per common share, compared to $810 million, or $3.31 per common share, for the same period in 2021.
FAD for the year of $678 million, compared to FAD of $768 million for the same period in 2021.
Completed $238 million in real estate acquisitions.
Invested $96 million in three new loans.
Funded $70 million in capital renovation and construction-in-progress projects.
Repurchased 5 million common shares for $142 million.
Sold 77 facilities for $759 million in cash proceeds and $105 million in seller financing, generating a $360 million gain.
Paid a $0.67 per share quarterly cash dividend on common stock in February, May, August and November.

Nareit FFO, AFFO and FAD are supplemental non-GAAP financial measures that the Company believes are useful in evaluating the performance of real estate investment trusts (“REITs”). Reconciliations and further information regarding these non-GAAP measures are provided at the end of this press release.

CEO COMMENTS

Taylor Pickett, Omega’s Chief Executive Officer, stated, “Our fourth quarter financial performance was materially in line with our prior quarter, as we continued to work through operator restructurings. As we previously announced, our first quarter earnings will be further impacted by deferred rents associated with additional operator restructurings. We expect this will result in a decline in our first quarter earnings and a related increase in our dividend payout ratio. Barring additional unforeseen restructurings, we would expect our operating performance to improve as the year progresses and operator restructurings are completed. However, with both facility occupancy and profitability still meaningfully below pre-pandemic levels, the risk of further operator issues remains.”

Mr. Pickett continued, “The operating backdrop seems to be slowly improving. Portfolio occupancy continues to grow, albeit modestly, as the labor market gradually improves. Many states have also implemented much needed Medicaid reimbursement rate increases, for which the industry is grateful. However, with inflation still at elevated levels, it is vitally important that federal and state fundings continue to reflect the challenging cost environment facing the industry.”

Mr. Pickett concluded, “Still, we remain constructive on our business longer-term. As a low-cost provider of post-acute care, the skilled nursing industry is an integral part of the healthcare continuum and an important tool in the effort to meet increasing clinical needs at a manageable price. We believe the industry is well positioned to benefit from multi-decade demographic tailwinds, and we will continue to work with our operators to help them meet this increased demand.”

FOURTH QUARTER 2022 RESULTS

Revenues – Revenues for the quarter ended December 31, 2022 totaled $144.8 million, a decrease of $105.1 million over the same period in 2021. The decrease primarily resulted from (i) incremental write-offs of straight-line accounts receivable and lease inducements in 2022 as a result of placing LaVie Care Centers, LLC (“LaVie,” f/k/a Consulate Health Care), Maplewood Senior Living (“Maplewood”) and two other operators on a cash basis for revenue recognition, (ii) asset sales completed throughout 2021 and 2022, (iii) operator restructurings and (iv) no rental income in the fourth quarter of 2022 from Agemo Holdings, LLC (“Agemo”); see “Operator Updates” below. The decrease was partially offset by revenue from new investments completed throughout 2021 and 2022.

Expenses – Expenses for the quarter ended December 31, 2022 totaled $280.1 million, an increase of $63.5 million over the same period in 2021. The increase primarily resulted from (i) a $36.3 million increase in acquisition, merger and transition related costs related primarily to the LaVie portfolio restructure, (ii) a $15.0 million increase in impairment on real estate properties, (iii) a $14.6 million increase in the provision for credit losses and (iv) a $2.3 million increase in stock-based compensation expense, partially offset by (i) a $4.2 million decrease in general and administrative (“G&A”) expense primarily related to $2.7 million of severance costs booked in 2021 and (ii) a $1.5 million decrease in depreciation and amortization expense primarily related to facility sales and facilities reclassified as held for sale.

Other Income and Expense – Other income for the quarter ended December 31, 2022 totaled $183.2 million, an increase of $182.9 million over the same period in 2021. The increase primarily resulted from a $179.2 million increase in gain on assets sold.

Net Income – Net income for the quarter ended December 31, 2022 totaled $46.7 million, an increase of $12.5 million over the same period in 2021. The increase primarily resulted from the aforementioned $182.9 million increase in other income and expense partially offset by (i) the $105.1 million decrease in total revenue, (ii) the $63.5 million increase in expenses and (iii) a $1.8 million decrease in income from unconsolidated joint ventures.


2022 ANNUAL RESULTS

Revenues – Revenues for the year ended December 31, 2022 totaled $878.2 million, a decrease of $184.6 million over the same period in 2021. The decrease primarily resulted from (i) incremental straight-line accounts receivable and lease inducement write-offs in 2022 primarily as a result of placing LaVie, Maplewood and seven other operators on a cash basis of revenue recognition, (ii) asset sales completed throughout 2021 and 2022, (iii) operator restructurings and (iv) no rental income or interest income recognized in 2022 from Agemo; see “Operator Updates” below. The decrease was partially offset by revenue from new investments completed throughout 2021 and 2022.

Expenses – Expenses for the year ended December 31, 2022 totaled $799.7 million, an increase of $22.7 million over the same period in 2021. The increase primarily resulted from (i) a $40.2 million increase in acquisition, merger and transition related costs related primarily to the LaVie portfolio restructure, (ii) a $5.9 million increase in stock-based compensation expense and (iii) a $3.3 million increase in real estate tax and ground lease expense, partially offset by (i) a $9.6 million decrease in depreciation and amortization expense related to facility sales and facilities reclassified as held for sale, (ii) a $9.1 million decrease in provision for credit losses, (iii) a $6.2 million decrease in impairment on real estate properties and (iv) a $2.0 million decrease in interest expense.

Other Income and Expense – Other income for the year ended December 31, 2022 totaled $357.6 million, an increase of $227.3 million over the same period in 2021. The increase primarily resulted from a $198.3 million increase in gain on assets sold.

Net Income – Net income for the year ended December 31, 2022 totaled $438.8 million, an increase of $10.5 million over the same period in 2021. The increase primarily resulted from the aforementioned (i) $227.3 million increase in other income and expense partially offset by (i) the $184.6 million decrease in total revenue, (ii) the $22.7 million increase in expenses and (iii) the $8.8 million decrease in income from unconsolidated joint ventures.

FINANCING ACTIVITIES

$500 Million Stock Repurchase Program – The following is a summary of the 2022 quarterly common share repurchases through December 31:

Stock Repurchase Program for 2022

(in thousands, except price per share)

Q1

Q2

Q3

Q4

Total

Number of shares

981

4,227

5,208

Average price per share

$

27.84

$

27.19

$

$

$

27.32

Repurchase cost

$

27,321

$

114,946

$

$

$

142,267

Dividend Reinvestment and Common Stock Purchase Plan – The following is a summary of the 2022 quarterly common shares issued under the Dividend Reinvestment and Common Stock Purchase Plan through December 31:

Dividend Reinvestment and Common Stock Purchase Plan for 2022

(in thousands, except price per share)

Q1

Q2

Q3

Q4

Total

Number of shares

80

85

71

72

308

Average price per share

$

28.45

$

27.91

$

32.80

$

31.11

$

29.93

Gross proceeds

$

2,273

$

2,363

$

2,335

$

2,258

$

9,229


2022 FOURTH QUARTER PORTFOLIO AND RECENT ACTIVITY

Operator Updates:

LaVie – In the fourth quarter of 2022, Omega began the process of restructuring its portfolio with LaVie. On December 30, 2022, the Company sold 11 facilities previously subject to a lease agreement with LaVie to a third party for a sales price of $129.8 million and provided $104.8 million of seller financing bearing interest at 8% with a December 29, 2027 maturity. In connection with the restructuring, Omega agreed to provide LaVie a $35.0 million transition fee in the fourth quarter of 2022 in connection with the sale of these facilities and expected future facility sales; $25.0 million of this fee was assumed and paid by the buyer of the 11 facilities, rather than Omega, as part of the consideration of the transaction. Concurrent with the sale, Omega also amended its lease agreement with LaVie to reduce the contractual rent from $8.3 million to $7.3 million per month and to provide Omega a rent reset if LaVie meets certain financial metrics at any time after February 1, 2027. Omega’s two term loan agreements with LaVie, with $32.5 million in aggregate principal outstanding, were also amended to extend the maturity dates to November 2036, reduce the interest rates to 2%, convert from monthly cash interest payment to payment-in-kind interest and to remove the requirement for principal payments before the maturity date. The restructuring discussions are still ongoing, but the Company anticipates additional restructuring activity related to this operator in 2023. As a result of the restructuring activities during 2022 and future expected restructuring activities, during the fourth quarter of 2022, Omega placed LaVie on a cash basis of revenue recognition, recorded the $24.8 million received for rent in the quarter and wrote off approximately $58.0 million of straight-line rent receivables and lease inducements to rental income. The Company also recorded a $23.3 million provision for credit losses related to LaVie’s term loans in the fourth quarter of 2022. In the first quarter of 2023, the Company agreed to allow LaVie to defer up to 66% of contractual rent from January 2023 through April 2023.

Maplewood – In the first quarter of 2023, the Company entered into a restructuring agreement to amend and restate its master lease and loan agreement with Maplewood. As part of the restructuring agreement and amendments, Omega and Maplewood agreed, among other terms, to (i) fix contractual rent at $69.3 million per annum and defer the annual 2.5% escalators through December 31, 2025, (ii) convert the 7% per annum cash interest due on the loan to PIK only interest in 2023 with cash interest payments to be phased in starting in 2024 and (iii) increase the capacity of the loan from $250.5 million to $320.0 million, inclusive of PIK interest. As a result of the negotiations, during the fourth quarter of 2022, the Company placed Maplewood on a cash basis of revenue recognition, recorded the $20.2 million received for rent and interest, and wrote off approximately $29.3 million of straight-line rent receivables and lease inducements to rental income.

Agemo During the fourth quarter of 2022, Agemo continued to not pay its contractual rent and interest due under its lease and loan agreements, and as a result, the Company did not recognize revenue related to this operator. During the fourth quarter of 2022, the Company sold 20 facilities that were previously leased to Agemo for $316 million in net proceeds; bringing the 2022 total Agemo assets sold to 22 facilities for $359 million in net proceeds. In the first quarter of 2023, the Company entered into a restructuring agreement, in which Omega and Agemo agreed, among other terms, to (i) reduce annual base rent and interest to $27.9 million commensurate with the sale of the 22 facilities in 2022 and (ii) defer Agemo’s requirement to pay rent and interest until April 1, 2023.

Healthcare Homes – During the fourth quarter of 2022, the Company agreed to allow Healthcare Homes Limited (“Healthcare Homes”), a U.K. based operator representing 2.5% of fourth quarter 2022 annualized contractual rent and mortgage interest, the ability to defer up to £6.7 million of contractual rent from January 2023 through April 2023 with regular payments to resume in May 2023. The deferred rent balance accrues interest monthly at a rate of 8% per annum and must be fully repaid by December 31, 2024.

Other Operators – As previously disclosed, an operator representing 2.4% of the Company’s first quarter 2022 annualized contractual rent and interest revenue was placed on a cash basis in the second quarter of 2022 after the operator failed to make full contractual rent payments. In the fourth quarter, the operator continued to under-pay rent and paid only $1.5 million, which was recorded for both adjusted FFO and FAD purposes. In January 2023, the operator paid $0.5 million of the $2.0 million of contractual rent due. Omega expects to finalize the transition of this portfolio during the first quarter of 2023.


Also, as previously disclosed, an operator representing 2.2% of the Company’s second quarter 2022 annualized contractual rent and interest revenue was placed on a cash basis in the third quarter of 2022 after Omega allowed the operator to apply a $5.4 million letter of credit towards unpaid contractual rent. In the fourth quarter of 2022, the operator paid $2.3 million in cash rent and the Company applied the remaining $1.5 million using the proceeds from the letter of credit, which are fully exhausted. As the operator is on a cash basis, the Company recognized $3.8 million in revenue, adjusted FFO and FAD for the cash received and the cash collateral applied to rent in the fourth quarter of 2022. This operator paid $0.3 million in contractual rent in January 2023.

In the fourth quarter of 2022, the Company transitioned three facilities to an existing operator for an initial annual rent of $1.6 million. On February 1, 2023, the Company transitioned 16 of the remaining 20 facilities previously leased to the 2.2% operator to one new and one existing operator for a combined annual rent of $11.2 million. The remaining four facilities are in negotiations to transition to a new operator in the first quarter of 2023.

Other Industry News – On January 30, 2023, it was announced that the COVID-19 Public Health Emergency (“PHE”) will end on May 11, 2023. The PHE provided a number of benefits to the industry that will end with its conclusion. The impact on individual operators will vary, and therefore it is not possible to quantify the financial impact it will have on portfolio coverage. However, we expect this will be a modest but incremental headwind to the financial performance of most of our skilled nursing tenants.

New Investments:

The following table presents real estate investment activity:

Three Months Ended

Year Ended

Real Estate Investment Activity ($000's)

December 31, 2022

December 31, 2022

$ Amount

    

%

    

$ Amount

    

%

Real property

$

88,509

85.5

%

$

238,199

58.9

%

Construction-in-progress

5,772

 

5.6

%

22,480

 

5.6

%

Capital expenditures

 

9,168

 

8.9

%

 

47,981

 

11.9

%

Mortgages

%

%

Other

 

 

%

 

95,600

 

23.6

%

Total

$

103,449

 

100.0

%

$

404,260

 

100.0

%

$89 Million Real Estate Acquisition – On December 1, 2022, the Company acquired one facility in Pennsylvania and six facilities in North Carolina for $88.5 million. Concurrent with the acquisition, the Company amended an existing operator’s master lease to include the seven acquired facilities. The incremental base rent for the additional facilities is $7.9 million per annum and includes annual escalators of 2%.

Asset Sales and Impairments:

$321 Million in Asset Sales – In the fourth quarter of 2022, the Company sold 33 facilities for $320.8 million in cash and $104.8 million in seller financing, recognizing a gain of $180.2 million. Twenty of these facilities were previously classified as held for sale. The sale of 11 facilities, previously leased to LaVie, and the related $104.8 million seller financing were not recognized for accounting purposes as the sale and related seller financing did not meet the accounting criteria to be recognized as a sale and therefore the assets will remain on the balance sheet and the cash interest payments received on the seller’s note will not be included in revenue, but will be added back for purposes of adjusted FFO and FAD.

Impairments and Assets Held for Sale – During the fourth quarter of 2022, the Company recorded a $17.2 million net impairment charge, in connection with the LaVie portfolio restructuring to reduce the net book value of 12 facilities to their estimated fair value.

As of December 31, 2022, the Company had two facilities classified as assets held for sale, totaling $9.5 million in net book value. One of the two facilities was sold on January 6, 2023 for $20 million.


RECLASSIFICATION

Effective for the fourth quarter of 2022, the Company adjusted its presentation of certain financial statement line items on its Consolidated Balance Sheet to better align with similar companies in the healthcare real estate space. Mortgage notes receivable – net has been renamed Real estate loans receivable – net, Other investments – net has been renamed Non-real estate loans receivable – net, and certain loans have been reclassified out of Other Investments – net into Real estate loans receivable – net. Specifically, other real estate loans collateralized by second or third mortgage liens, a leasehold mortgage on, or an assignment of partnership interest in the related properties that were previously presented in Other Investments – net are now presented in Real estate loans receivable – net. See the table below for the prior presentation compared to the current presentation of our real estate (“RE”) and non-RE loans.

Prior Presentation

Current Presentation

December 31, 2021

December 31, 2021

(in thousands)

(in thousands)

Mortgage notes receivable – net

$

835,086

Mortgage notes receivable – net

$

835,086

Other investments – net

469,884

Leasehold mortgages and other RE loans – net

345,700

Total

$

1,304,970

RE loans receivable – net

$

1,180,786

Non-RE loans receivable – net

$

124,184

Total

$

1,304,970

OPERATOR COVERAGE DATA

The following tables present operator revenue mix, census and coverage data based on information provided by our operators for the indicated periods. We have not independently verified this information, and we are providing this data for informational purposes only.

Operator Revenue Mix (1)

    

  

Medicare /

Private /

Medicaid

Insurance

Other

Three-months ended September 30, 2022

 

53.4

%  

31.5

%  

15.1

%

Three-months ended June 30, 2022

 

53.5

%  

31.5

%  

15.0

%

Three-months ended March 31, 2022

 

51.0

%  

35.8

%  

13.2

%

Three-months ended December 31, 2021

 

54.3

%  

32.2

%  

13.5

%

Three-months ended September 30, 2021

 

53.1

%  

33.3

%  

13.6

%


(1)Excludes all facilities considered non-core and does not include federal stimulus revenue. For non-core definition, see Fourth Quarter 2022 Financial Supplemental posted in the “Quarterly Supplements” section of Omega’s website.

Coverage Data

    

    

Before

After

Occupancy (2)

Management

Management

Operator Census and Coverage (1)

Fees (3)

Fees (4)

Twelve-months ended September 30, 2022

 

76.2

%  

1.37x

1.04x

Twelve-months ended June 30, 2022

 

75.8

%  

1.39x

1.06x

Twelve-months ended March 31, 2022

 

75.1

%  

1.44x

1.10x

Twelve-months ended December 31, 2021

 

74.5

%  

1.48x

1.14x

Twelve-months ended September 30, 2021

 

74.2

%  

1.52x

1.18x


(1)Excludes facilities considered non-core.
(2)Based on available (operating) beds.
(3)Represents EBITDARM of our operators, defined as earnings before interest, taxes, depreciation, amortization, Rent costs and management fees for the applicable period, divided by the total Rent payable to the Company by its operators during such period. “Rent” refers to the total monthly contractual rent and mortgage interest due under the Company’s lease and mortgage agreements over the applicable period.
(4)Represents EBITDAR of our operators, defined as earnings before interest, taxes, depreciation, amortization, and Rent (as defined in footnote 3) expense for the applicable period, divided by the total Rent payable to the Company by its operators during such period. Assumes a management fee of 4%.

BALANCE SHEET AND LIQUIDITY

As of December 31, 2022, the Company had $5.3 billion of outstanding indebtedness with a weighted-average annual interest rate of 4.2%. The Company’s indebtedness consisted of an aggregate principal amount of $4.9 billion of senior unsecured notes, a $50.0 million unsecured term loan, $366.6 million of secured debt and $19.2 million of borrowings outstanding under its unsecured revolving credit facility. As of December 31, 2022, total cash and cash equivalents were $297.1 million, and the Company had $1.4 billion of undrawn capacity under its unsecured revolving credit facility.

DIVIDENDS

On January 26, 2023, the Board of Directors declared a quarterly cash dividend of $0.67 per share, to be paid February 15, 2023, to common stockholders of record as of the close of business on February 6, 2023.

ADDITIONAL INFORMATION

Additional information regarding the Company can be found in its Fourth Quarter 2022 Financial Supplemental posted in the “Quarterly Supplements” section of Omega’s website. The information contained on, or that may be accessed through Omega’s website, including the information contained in the aforementioned supplemental, is not incorporated by any reference into, and is not part of, this document.

CONFERENCE CALL

The Company will be conducting a conference call on Friday, February 3, 2023, at 10 a.m. Eastern time to review the Company’s 2022 fourth quarter results and current developments. Analysts and investors within the U.S. interested in participating are invited to call (877) 511-2891. The Canadian toll-free dial-in number is (855) 669-9657. All other international participants may use the dial-in number (412) 902-4140. Ask the operator to be connected to the “Omega Healthcare’s Fourth Quarter 2022 Earnings Call.”

To listen to the conference call via webcast, log on to www.omegahealthcare.com and click the “Omega Healthcare Investors, Inc. 4Q Earnings Call” hyper-link under “Upcoming Events” in the Investor Relations section on Omega’s website homepage. Webcast replays of the call will be available on Omega’s website for a minimum of two weeks following the call. Additionally, a copy of the earnings release will be available in the “Featured Documents” and “Press Releases” sections of Omega’s website.

* * * * * *

Omega is a REIT that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the U.S., as well as in the U. K.

FOR FURTHER INFORMATION, CONTACT

Matthew Gourmand, SVP, Corporate Strategy & Investor Relations

or

Bob Stephenson, CFO at (410) 427-1700



Forward-Looking Statements and Cautionary Language

This press release includes forward-looking statements within the meaning of the federal securities laws. All statements regarding Omega’s or its tenants’, operators’, borrowers’ or managers’ expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, expected lease income, continued qualification as a REIT, plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega's expectations.

Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) the impact of the Novel coronavirus (“COVID-19”) pandemic on our business and the business of our operators, including without limitation, the impact of the announced termination of the federally declared public health emergency and related government and regulatory support, the levels of staffing shortages, increased costs and decreased occupancy experienced by operators of skilled nursing facilities (“SNFs”) and assisted living facilities (“ALFs”) in connection with the pandemic, the ability of our operators to comply with infection control and vaccine protocols and to manage facility infection rates, and the sufficiency of government support and reimbursement rates to offset such costs and the conditions related thereto; (iii) the ability of any of Omega’s operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega’s mortgages and impede the ability of Omega to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations, and other costs and uncertainties associated with operator bankruptcies; (iv) Omega’s ability to re-lease, otherwise transition or sell underperforming assets or assets held for sale on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (v) the availability and cost of capital to Omega; (vi) changes in Omega’s credit ratings and the ratings of its debt securities; (vii) competition in the financing of healthcare facilities; (viii) competition in the long-term healthcare industry and shifts in the perception of various types of long-term care facilities, including SNFs and ALFs; (ix) additional regulatory and other changes in the healthcare sector; (x) changes in the financial position of Omega’s operators; (xi) the effect of economic and market conditions generally, and particularly in the healthcare industry; (xii) changes in interest rates or the impact of inflation; (xiii) the timing, amount and yield of any additional investments; (xiv) changes in tax laws and regulations affecting REITs; (xv) the potential impact of changes in the SNF and ALF market or local real estate conditions on the Company’s ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms; (xvi) Omega’s ability to maintain its status as a REIT; (xvii) the effect of other factors affecting our business or the businesses of Omega’s operators that are beyond Omega’s or operators’ control, including natural disasters, other health crises or pandemics and governmental action, particularly in the healthcare industry, and (xviii) other factors identified in Omega’s filings with the Securities and Exchange Commission. Statements regarding future events and developments and Omega’s future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward looking statements.

We caution you that the foregoing list of important factors may not contain all the material factors that are important to you. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are based upon information available to us on the date of this release. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.


OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

December 31, 

December 31, 

    

2022

    

2021

(Unaudited)

ASSETS

Real estate assets

Buildings and improvements

$

7,347,853

$

7,515,658

Land

923,605

919,180

Furniture and equipment

499,902

519,845

Construction in progress

88,904

74,062

Total real estate assets

8,860,264

9,028,745

Less accumulated depreciation

 

(2,322,773)

 

(2,181,528)

Real estate assets – net

 

6,537,491

 

6,847,217

Investments in direct financing leases – net

 

8,503

 

10,873

Real estate loans receivable – net

 

1,042,731

 

1,180,786

Investments in unconsolidated joint ventures

 

178,920

 

194,687

Assets held for sale

 

9,456

 

203,025

Total real estate investments

 

7,777,101

 

8,436,588

Non-real estate loans receivable – net

 

225,281

 

124,184

Total investments

 

8,002,382

 

8,560,772

Cash and cash equivalents

 

297,103

 

20,534

Restricted cash

 

3,541

 

3,877

Contractual receivables – net

 

8,228

 

11,259

Other receivables and lease inducements

 

177,798

 

251,815

Goodwill

 

643,151

 

651,417

Other assets

 

272,960

 

138,804

Total assets

$

9,405,163

$

9,638,478

LIABILITIES AND EQUITY

 

  

Revolving credit facility

$

19,246

$

Secured borrowings

 

366,596

 

362,081

Senior notes and other unsecured borrowings – net

 

4,900,992

 

4,891,455

Accrued expenses and other liabilities

 

315,047

 

276,716

Total liabilities

 

5,601,881

 

5,530,252

Equity:

 

  

Preferred stock $1.00 par value authorized – 20,000 shares, issued and outstanding – none

Common stock $.10 par value authorized – 350,000 shares, issued and outstanding – 234,252 shares as of December 31, 2022 and 239,061 shares as of December 31, 2021

 

23,425

 

23,906

Additional paid-in capital

 

6,314,203

 

6,427,566

Cumulative net earnings

 

3,438,401

 

3,011,474

Cumulative dividends paid

 

(6,186,986)

 

(5,553,908)

Accumulated other comprehensive loss (income)

 

20,325

 

(2,200)

Total stockholders’ equity

 

3,609,368

 

3,906,838

Noncontrolling interest

 

193,914

 

201,388

Total equity

 

3,803,282

 

4,108,226

Total liabilities and equity

$

9,405,163

$

9,638,478


OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

(in thousands, except per share amounts)

Three Months Ended

 

Year Ended

December 31, 

 

December 31, 

    

2022

    

2021

 

2022

    

2021

Revenues

 

  

 

  

  

 

  

Rental income

$

110,149

$

214,314

$

734,236

$

910,722

Real estate tax and ground lease income

 

4,159

 

3,483

 

15,972

 

12,955

Income from direct financing leases

 

255

 

257

 

1,023

 

1,029

Real estate loans interest income

 

24,955

 

29,347

 

110,322

 

123,649

Non-real estate loans interest income

 

5,103

 

2,097

 

13,597

 

12,733

Miscellaneous income

 

228

 

451

 

3,094

 

1,721

Total revenues

 

144,849

 

249,949

 

878,244

 

1,062,809

Expenses

 

  

 

  

 

  

 

  

Depreciation and amortization

 

83,739

 

85,269

 

332,407

 

342,014

General and administrative

 

8,840

 

13,036

 

40,626

 

41,757

Real estate tax and ground lease expense

 

4,373

 

3,624

 

16,969

 

13,716

Stock-based compensation expense

 

6,787

 

4,502

 

27,302

 

21,415

Acquisition, merger and transition related costs

 

36,348

 

 

42,006

 

1,814

Impairment on real estate properties

 

17,230

 

2,205

 

38,451

 

44,658

Recovery on direct financing leases

 

 

 

 

(717)

Provision for credit losses

 

64,296

 

49,710

 

68,663

 

77,733

Interest expense

 

55,238

 

55,062

 

220,296

 

222,316

Interest – amortization of deferred financing costs

 

3,251

 

3,163

 

12,948

 

12,288

Total expenses

 

280,102

 

216,571

 

799,668

 

776,994

Other income (expense)

 

  

 

  

 

  

 

  

Other income (loss) – net

 

3,041

 

(585)

 

(1,997)

 

(581)

Loss on debt extinguishment

 

 

(56)

 

(389)

 

(30,763)

Gain on assets sold – net

 

180,205

 

975

 

359,951

 

161,609

Total other income

 

183,246

 

334

 

357,565

 

130,265

Income before income tax expense and income from unconsolidated joint ventures

 

47,993

 

33,712

 

436,141

 

416,080

Income tax expense

 

(1,026)

 

(967)

 

(4,561)

 

(3,840)

(Loss) income from unconsolidated joint ventures

 

(261)

 

1,493

 

7,261

 

16,062

Net income

 

46,706

 

34,238

 

438,841

 

428,302

Net income attributable to noncontrolling interest

 

(1,127)

 

(947)

 

(11,914)

 

(11,563)

Net income available to common stockholders

$

45,579

$

33,291

$

426,927

$

416,739

Earnings per common share available to common stockholders:

 

  

 

  

 

  

 

  

Basic:

 

  

 

  

 

  

 

  

Net income available to common stockholders

$

0.19

$

0.14

$

1.81

$

1.76

Diluted:

 

 

  

 

 

  

Net income

$

0.19

$

0.14

$

1.80

$

1.75

Dividends declared per common share

$

0.67

$

0.67

$

2.68

$

2.68


OMEGA HEALTHCARE INVESTORS, INC.

Nareit FFO, Adjusted FFO and FAD Reconciliation

Unaudited

(in thousands, except per share amounts)

Three Months Ended

 

Year Ended

December 31, 

 

December 31, 

2022

    

2021

 

2022

    

2021

Net income (1)(2)

$

46,706

$

34,238

$

438,841

$

428,302

Deduct gain from real estate dispositions

(180,205)

(975)

(359,951)

(161,609)

Deduct gain from real estate dispositions of unconsolidated joint ventures

 

 

(135)

 

(93)

 

(14,880)

Sub-total

 

(133,499)

 

33,128

 

78,797

 

251,813

Elimination of non-cash items included in net income:

 

  

 

  

 

  

 

  

Depreciation and amortization

 

83,739

 

85,269

 

332,407

 

342,014

Depreciation - unconsolidated joint ventures

 

2,623

 

2,906

 

10,881

 

12,285

Add back provision for impairments on real estate properties

 

17,230

 

2,205

 

38,451

 

44,658

Add back provision for impairments on real estate properties of unconsolidated joint ventures

 

 

 

 

4,430

Add back unrealized loss on warrants

 

 

 

 

43

Nareit funds from operations (“Nareit FFO”)

$

(29,907)

$

123,508

$

460,536

$

655,243

Weighted-average common shares outstanding, basic

 

234,863

 

239,649

 

236,256

 

236,933

Restricted stock and PRSUs

 

1,378

 

430

 

1,198

 

785

Omega OP Units

 

6,752

 

6,837

 

6,836

 

6,620

Weighted-average common shares outstanding, diluted

 

242,993

 

246,916

 

244,290

 

244,338

Nareit funds from operations available per share

$

(0.13)

$

0.50

$

1.89

$

2.68

Adjustments to calculate adjusted funds from operations:

 

  

 

  

 

  

 

  

Nareit FFO

$

(29,907)

$

123,508

$

460,536

$

655,243

Add back:

Uncollectible accounts receivable (3)

 

96,133

 

16,449

 

124,758

 

38,806

Non-cash provision for credit losses

 

67,027

 

50,582

 

77,109

 

78,605

Stock-based compensation expense

 

6,787

 

4,502

 

27,302

 

21,415

Loss on debt extinguishment

56

 

389

 

30,763

Acquisition, merger and transition related costs

 

36,348

 

42,006

1,814

Non-recurring expense

722

 

3,722

Severance

2,721

2,721

Deduct:

Non-recurring revenue

 

(2,372)

 

(7,436)

 

(4,934)

 

(19,350)

Recovery on direct financing leases

 

 

 

 

(717)

Add back (deduct) unconsolidated joint venture related expense (revenue)

1,940

(645)

457

Adjusted funds from operations (“AFFO”) (1)(2)(4)

$

176,678

$

190,382

$

730,243

$

809,757

Adjustments to calculate funds available for distribution:

 

  

 

  

 

  

 

  

Non-cash interest expense

$

2,222

$

2,114

$

8,832

$

8,266

Capitalized interest

 

(859)

 

(720)

 

(3,158)

 

(1,524)

Non-cash revenue

 

(6,979)

 

(13,000)

 

(58,269)

 

(48,751)

Funds available for distribution (“FAD”) (1)(2)(4)

$

171,062

$

178,776

$

677,648

$

767,748


(1)The three months and year ended December 31, 2022 includes the application of $1.6 million and $11.0 million, respectively, of security deposits (letters of credit and cash deposits) in revenue. The three months and year ended December 31, 2021 includes the application of $0.1 million and $11.8 million, respectively, of security deposits (letter of credit and cash deposits) in revenue.
(2)The three months and year ended December 31, 2021 includes $14.8 million and $21.3 million of revenue related to Gulf Coast recognized based on our ability to offset uncollected rent against the interest and principal of certain debt obligations of Omega.
(3)Straight-line accounts receivable write-off recorded as a reduction to rental income.
(4)Adjusted funds from operations per share and funds available for distribution per share can be calculated using weighted-average common shares outstanding, diluted shown above.


Nareit Funds From Operations (“Nareit FFO”), Adjusted FFO and Funds Available for Distribution (“FAD”) are non-GAAP financial measures. As used in this press release, GAAP refers to generally accepted accounting principles in the United States of America. The Company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company calculates and reports Nareit FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“Nareit”), and consequently, Nareit FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures and changes in the fair value of warrants. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. Revenue recognized based on the application of security deposits and letters of credit or based on the ability to offset against other financial instruments is included within Nareit FFO. The Company believes that Nareit FFO, Adjusted FFO and FAD are important supplemental measures of its operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. The term funds from operations was designed by the real estate industry to address this issue. Funds from operations described herein is not necessarily comparable to funds from operations of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.

Adjusted FFO is calculated as Nareit FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items (e.g., acquisition, merger and transition related costs, write-off of straight-line accounts receivable, recoveries and provisions for credit losses (excluding certain cash recoveries on impaired loans), cash interest received but not included in revenue, severance, legal reserve expenses, etc.). FAD is calculated as Adjusted FFO less non-cash interest expense and non-cash revenue, such as straight-line rent. The Company believes these measures provide an enhanced measure of the operating performance of the Company’s core portfolio as a REIT. The Company’s computation of Adjusted FFO and FAD may not be comparable to the Nareit definition of funds from operations or to similar measures reported by other REITs, but the Company believes that they are appropriate measures for this Company.

The Company uses these non-GAAP measures among the criteria to measure the operating performance of its business. The Company also uses FAD among the performance metrics for performance-based compensation of officers. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs, and which may be of limited relevance in evaluating current performance, funds from operations can facilitate comparisons of operating performance between periods and between other REITs. The Company offers these measures to assist the users of its financial statements in analyzing its operating performance and not as measures of liquidity or cash flow. These non-GAAP measures are not measures of financial performance under GAAP and should not be considered as measures of liquidity, alternatives to net income or indicators of any other performance measure determined in accordance with GAAP. Investors and potential investors in the Company’s securities should not rely on these non-GAAP measures as substitutes for any GAAP measure, including net income.


GRAPHIC 3 ohi-20230202xex99d1001.jpg GRAPHIC begin 644 ohi-20230202xex99d1001.jpg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end EX-101.SCH 4 ohi-20230202.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 ohi-20230202_def.xml EX-101.DEF EX-101.LAB 6 ohi-20230202_lab.xml EX-101.LAB EX-101.PRE 7 ohi-20230202_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Feb. 02, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Feb. 02, 2023
Entity Registrant Name OMEGA HEALTHCARE INVESTORS, INC.
Entity Central Index Key 0000888491
Entity Incorporation, State or Country Code MD
Entity File Number 1-11316
Entity Tax Identification Number 38-3041398
Amendment Flag false
Entity Emerging Growth Company false
Entity Address, Address Line One 303 International Circle,
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Hunt Valley
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21030
City Area Code 410
Local Phone Number 427-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OHI
Security Exchange Name NYSE
XML 9 ohi-20230202x8k_htm.xml IDEA: XBRL DOCUMENT 0000888491 2023-02-02 2023-02-02 0000888491 false 8-K 2023-02-02 OMEGA HEALTHCARE INVESTORS, INC. MD 1-11316 38-3041398 303 International Circle, Suite 200 Hunt Valley MD 21030 410 427-1700 false false false false false Common Stock OHI NYSE EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $:%0E8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !&A4)6@!,7K>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OITG%0^CFLN))07!!\1:2V=U@TX9DI-VW-XV[740?0,@E,W^^ M^0;2F2#-&/$YC@$C.4PWL^^')$W8L"-1D #)'-'K5.?$D)O[,7I-^1H/$+3Y MT <$T31WX)&TU:1A 59A)3+562--1$UC/..M6?'A,_8%9@U@CQX'2L!K#DPM M$\-I[CNX A888?3INX!V)9;JG]C2 79.SLFMJ6F:ZJDMN;P#A[>GQY>R;N6& M1'HPF%\E)^D4<,,NDU_;[?WN@2G1B+9J1#X[P>6MD%R\+ZX__*["?K1N[_ZQ M\450=?#K7Z@O4$L#!!0 ( $:%0E:97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M1H5"5B)=B)5E! 1A$ !@ !X;"]W;W)K)NJZ,53YD^DSG/ MX)N%5"DS<*F6KLX59W$Y*$UC)PB0BXU-%=)&F3'W< M\$2N^PYU=C=>Q')E[ UWT,O9DH?<_)Y/%5RYE4HL4IYI(3.B^*+O#.GUC7]N M!Y0]7@5?Z[TVL:\RE_*KO9C$?<>S1#SAD;$2##[>^(@GB54"CF];4:=ZIAVX MW]ZIWY4O#R\S9YJ/9/)%Q&;5=[H.B?F"%8EYD>M[OGVA$C"2B2[_D_6F;Z?C MD*C01J;;P4"0BFSSR=ZW$[$W( @.#/"W _R2>_.@DO*6&3;H*;DFRO8&-=LH M7[4<#7 BLU$)C8)O!8PS@UL9%3#)AK L)N/,"/-!)MDFVC!K/=? 0VQ7-]H* MWFP$_0."=WQ^1CS_A/B>'WP_W 6V"M"O /U2+_AO@.2OX5P;!<']NXEUH]UI MUK89?ZUS%O&^ RFMN7KCSN#GG^B%]QM"'E3D :9>D\\^^%#:$ /G$TD8R7.?Y M? M^4<3+*[DP5^WV^U<403KLL*Z/ 9KDD52Y5*5*^*$A 8"3*0B(UD +V#+N'%: M@IY0&] *AN:IHKHZAF;%W,HDAEF(A MHHV-'&;#%8/N:>!U:'#51?"H5[NQA\H-8:W&Y7J]2]BRT7UQ@05+-,=0]@H# M/6:NQBE72Y$MR2=0,"O(I31G66/BMPBVHM4E@:*^O4,;QC&XMC[9-<@#]"// M66.NMT@&7@#+R'"5E?D :WPD5)3P$PRXK@04]W(4>+:6C<"X9%@(6.2P^<( MZRI!<7/_$7!DK\!!9G+=O ? Y>[!=\@K2Y(?'?)[O+I0T*,J1857.=Q4R3>1 M1Z-U8:!'588*;2JU@>SY4^0';;=%T:=>@$:UK@X4=_ RBD/8K!]& MP04Z% 6IBP#%'?Q!1C GTY7,L"K0(M+Q+T_I)9[P=2&@N&]_4<(8GED[2XML M6P5T(Q4NU.9J?NW]/F[=H4Q$)(SUVD=(;R58TKBE_7\%P*\+@(_[]53QTPBF MA\/ZVNQCH39Q19X7B^;XM>BUDNT="7"S_A?91.L"R%H!<=E6P-KO?=R<9\+ M?D8G;$]"(Z.O&%KM]#YNS3/%8IMBX4&1V8W,IHD M? $ZWMDER*K-H7US861>'I3GTL"QNVRN.(.,LAW@^X649G=AS][53R>#?P!0 M2P,$% @ 1H5"5I^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>Q MS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G M55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4 M)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(R MA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[ M##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R M 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0< MO(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q M]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9 MQP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR M'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH< M8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ 1H5"5I>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_2 M36P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88!.R '<(Y M_A^[<#K3P&]'@!6^AC(,=D", MY1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;! M<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L M>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI M>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% @ 1H5"5B0>FZ*M M^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1& M:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T M==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+) M(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( $:%0E9ED'F2 M&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N M+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78 ME!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')O MJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1< M^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!G MZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%. M6X.^DT K @ $0 M @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " !& MA4)6F5R<(Q & "<)P $P @ '+ 0 >&PO=&AE;64O=&AE M;64Q+GAM;%!+ 0(4 Q0 ( $:%0E8B78B5900 $81 8 M " @0P( !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " !&A4)699!YDAD! #/ P $P M @ &]$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ( '% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ohi-20230202x8k.htm ohi-20230202.xsd ohi-20230202_def.xml ohi-20230202_lab.xml ohi-20230202_pre.xml ohi-20230202xex99d1.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ohi-20230202x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "ohi-20230202_def.xml" ] }, "inline": { "local": [ "ohi-20230202x8k.htm" ] }, "labelLink": { "local": [ "ohi-20230202_lab.xml" ] }, "presentationLink": { "local": [ "ohi-20230202_pre.xml" ] }, "schema": { "local": [ "ohi-20230202.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ohi", "nsuri": "http://www.omegahealthcare.com/20230202", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ohi-20230202x8k.htm", "contextRef": "Duration_2_2_2023_To_2_2_2023_HQRS440p8EC-GQKAfJlIdg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ohi-20230202x8k.htm", "contextRef": "Duration_2_2_2023_To_2_2_2023_HQRS440p8EC-GQKAfJlIdg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0000888491-23-000003-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000888491-23-000003-xbrl.zip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end